A citation-based method for searching scientific literature

Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins. Diabetes Care 2018
Times Cited: 116



Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 95




List of shared articles



Times cited

Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA.
Muhammad Muneer, Ijaz Akbar. Adv Exp Med Biol 2021
2


The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
3

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Moshe Phillip, Chantal Mathieu, Marcus Lind, Eiichi Araki, Paolo di Bartolo, Richard Bergenstal, Simon Heller, Lars Hansen, Markus Florian Scheerer, Fredrik Thoren,[...]. Diabetes Obes Metab 2021
6

Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
2


A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.
Ahmed Abu-Zaid, Abdulaziz Khalaf Altowairqi, Thusharika Dissanayaka, Artem Oganesyan, Akshaya Srikanth Bhagavathul, Habeeb Alhabeeb, Amirah Baradhwan, Sara Alomar, Sebastian Tom. Pharmacol Res 2021
0

The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.
Józef Drzewoski, Markolf Hanefeld. Pharmaceuticals (Basel) 2021
6

Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
1

Current and future therapies for type 1 diabetes.
Bernt Johan von Scholten, Frederik F Kreiner, Stephen C L Gough, Matthias von Herrath. Diabetologia 2021
8

Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 Inhibitor.
Rhea Teng, Martin Kurian, Kelly L Close, John B Buse, Anne L Peters, Charles M Alexander. Diabetes Spectr 2021
0

Double Diabetes: A Growing Problem Requiring Solutions.
Djordje S Popovic, Nikolaos Papanas. Exp Clin Endocrinol Diabetes 2021
0


A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes.
Curtis K Johnston, Rena J Eudy-Byrne, Ahmed Elmokadem, Valerie Nock, Jan Marquard, Nima Soleymanlou, Matthew M Riggs, Karl-Heinz Liesenfeld. Pharmaceutics 2021
0

Euglycemic diabetic ketoacidosis: A missed diagnosis.
Prashant Nasa, Sandeep Chaudhary, Pavan Kumar Shrivastava, Aanchal Singh. World J Diabetes 2021
1

Using adjuvant pharmacotherapy in the treatment of type 1 diabetes.
Åke Sjöholm. Expert Opin Pharmacother 2021
0

Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges.
Nuria Vilarrasa, Patricia San Jose, Miguel Ángel Rubio, Albert Lecube. Diabetes Metab Syndr Obes 2021
0

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
David Z I Cherney, Ele Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal. Diabetes Obes Metab 2021
0

Effect of short-term use of dapagliflozin on impaired awareness of hypoglycaemia in people with type 1 diabetes.
Lian A van Meijel, Cees J Tack, Bastiaan E de Galan. Diabetes Obes Metab 2021
0


Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
Thomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, Frederik F Kreiner, Lars Bardtrum, Matthias von Herrath, Chantal Mathieu, Sten Madsbad. Diabetes Obes Metab 2021
0

Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy.
Melissa-Rosina Pasqua, Michael A Tsoukas, Ahmad Haidar. J Diabetes Sci Technol 2021
0

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Christian Hampp, Richard S Swain, Casie Horgan, Elizabeth Dee, Yandong Qiang, Sarah K Dutcher, Andrew Petrone, Rong Chen Tilney, Judith C Maro, Catherine A Panozzo. Diabetes Care 2020
17

12th Roche Diabetes Care Network Meeting: April 11-13, 2019, Copenhagen, Denmark.
Christopher G Parkin, Christine Zepezauer, Rolf Hinzmann. Diabetes Technol Ther 2020
0


Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge.
C David Mazer, Amel Arnaout, Kim A Connelly, Jeremy D Gilbert, Stephen A Glazer, Subodh Verma, Ronald M Goldenberg. Curr Opin Cardiol 2020
1

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
15

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer R Snaith, Deborah J Holmes-Walker, Jerry R Greenfield. Trends Endocrinol Metab 2020
8

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
13



Treatment strategies for hypertension in patients with type 1 diabetes.
Alexandra Katsimardou, Konstantinos Imprialos, Konstantinos Stavropoulos, Alexandros Sachinidis, Michalis Doumas, Vasilios G Athyros. Expert Opin Pharmacother 2020
3


Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
Kana N Miyata, Shuiling Zhao, Chin-Han Wu, Chao-Sheng Lo, Anindya Ghosh, Isabelle Chenier, Janos G Filep, Julie R Ingelfinger, Shao-Ling Zhang, John S D Chan. Diabetes Res Clin Pract 2020
4


Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona. Diabetes Obes Metab 2020
14

Euglycemic Ketoacidosis.
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini. Curr Diab Rep 2020
5

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
2

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
5

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2.
Helena W Rodbard, Andrea Giaccari, Rosemarie Lajara, John Stewart, Paul S Strumph, Juliana Oliveira, Pablo Lapuerta, Rita Castro. Diabetes Obes Metab 2020
4

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
1


Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2


SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.
Birgit Janssens, Simon Caerels, Chantal Mathieu. Ther Adv Endocrinol Metab 2020
4

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.
Raffaella Buzzetti, Tiinamaija Tuomi, Didac Mauricio, Massimo Pietropaolo, Zhiguang Zhou, Paolo Pozzilli, Richard David Leslie. Diabetes 2020
14

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes.
Pieter Gillard, Oliver Schnell, Per-Henrik Groop. Diabetes Res Clin Pract 2020
2


An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.
Georgios Chatzopoulos, Konstantinos Tziomalos. Expert Opin Pharmacother 2020
1